Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up

Ann Hematol. 2021 Feb;100(2):595-599. doi: 10.1007/s00277-020-04181-5. Epub 2020 Jul 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Azacitidine / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic / adverse effects*
  • Cytarabine / therapeutic use
  • Decitabine / therapeutic use
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / physiopathology
  • Male
  • Middle Aged
  • Risk Factors
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects*
  • Tumor Lysis Syndrome / etiology*

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • Cytarabine
  • Decitabine
  • Azacitidine
  • venetoclax